Leerink Partners Initiates Coverage On Neumora Therapeutics with Outperform Rating, Announces Price Target of $8
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Leerink Partners analyst Marc Goodman initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Outperform rating and announces Price Target of $8.
Leerink Partners analyst Marc Goodman initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Outperform rating and announces Price Target of $8.